Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study

Yelena Yuriy Janjigian, Patrick Alexander Ott, Emiliano Calvo, Joseph W. Kim, Paolo Antonio Ascierto, Padmanee Sharma, Katriina Johanna Peltola, Dirk Jaeger, T.R. Jeffry Evans, Filippo G. De Braud, Ian Chau, Marina Tschaika, Christopher T. Harbison, Weiguo Cai, Johanna C. Bendell, Dung T. Le

Memorial Sloan Kettering Cancer Center, New York, NY
Dana-Farber Cancer Institute, Boston, MA
START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
Yale Cancer Center, New Haven, CT
Istituto Nazionale Tumori “Fondazione G.Pascale”- IRCCS, Naples, Italy
MD Anderson Cancer Center, Houston, TX
Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
Royal Marsden Hospital, London, United Kingdom
Bristol-Myers Squibb, Princeton, NJ
Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD